Greiner-Vacuette 2.0 mL Blue Top Collection Tube containing 3.2% Sodium Citrate. Tube must be filled to the line marked on the tube (2.0 mL).
For this test, a waste tube must be drawn. If sample collection is by venipuncture (preferred), collect a discard tube of at least 2 mLs before collecting 2 Greiner tubes that are filled to the intended capacity (indicated by the small black line.) If the sample is collected from indwelling catheters, at least 5mLs need to be discarded before collection of the 2 Griener tubes
Unacceptable Conditions
Serum. EDTA plasma, clotted or hemolyzed specimens &/or improperly labeled or filled collection tube. Spun or refrigerated tube. Mislabeled specimen, >4 hours from time of collection.
Storage/Transport Temperature
Specimen should be stored at room temperature (18-24 °C). Specimen must be transported to testing laboratory within 4 hours of collection at room temperature (18-24 °C).
Stability (from collection to initiation)
Specimen is stable at room temperature (18-24 °C) for 4 hours.
Cerner Orderable(s)
P2Y12 Platelet Function
Performed
Morton Plant Hospital and St. Joseph's Hospital
24/7
Ordering Recommendations
The P2Y12 Assay is designed to measure platelet P2Y12 receptor blockade. Substances known to specifically block the P2Y12 receptor include the thienopyridine class of drugs, including clopidogrel (Plavix®)
Methodology
The assay is based on the ability of activated platelets to bind fibrinogen. Fibrinogen-coated microparticles aggregate in whole blood in proportion to the number of expressed platelet GPIIb/IIIa receptors. The reagent is formulated to specifically measure P2Y12-mediated platelet aggregation. Light transmittance increases as activated platelets bind and aggregate fibrinogen-coated beads. The instrument measures this change in optical signal and reports results in P2Y12 Reaction Units (PRU).
Reference Interval
P2Y12 Plt Function Reference Interval: 194-418 PRU
Interpretive Data
Test results are reported in P2Y12 Reaction Units (PRU). The PRU is a measure of platelet aggregation in the presence of P2Y12 inhibitor drug. A lower PRU is associated with a higher platelet blockade by the inhibitor. Data in the literature suggests that a PRU of greater than 208 may be associated with a higher risk of adverse events in a patient that has received percutaneous coronary intervention. However, as there is inter-individual variability in this assay, the test should be interpreted in the clinical context.
Glycoprotein IIb/IIIa inhibitor drugs can interfere with this assay. The test should not be used in patients until 14 days after discontinuation of abciximab and until 48 hours after discontinuation of eptifibatide and triofiban.
This assay is not intended for evaluation of inherited platelet disorders, such as Von Willebrand Factor Deficiency, Glanzmann Thrombasthenia and Bernard-Soulier Syndrome.
CPT Codes
85576x2
Collection
Collect
Greiner-Vacuette 2.0 mL Blue Top Collection Tube containing 3.2% Sodium Citrate. Tube must be filled to the line marked on the tube (2.0 mL).
For this test, a waste tube must be drawn. If sample collection is by venipuncture (preferred), collect a discard tube of at least 2 mLs before collecting 2 Greiner tubes that are filled to the intended capacity (indicated by the small black line.) If the sample is collected from indwelling catheters, at least 5mLs need to be discarded before collection of the 2 Griener tubes
Unacceptable Conditions
Serum. EDTA plasma, clotted or hemolyzed specimens &/or improperly labeled or filled collection tube. Spun or refrigerated tube. Mislabeled specimen, >4 hours from time of collection.
Storage/Transport Temperature
Specimen should be stored at room temperature (18-24 °C). Specimen must be transported to testing laboratory within 4 hours of collection at room temperature (18-24 °C).
Stability (from collection to initiation)
Specimen is stable at room temperature (18-24 °C) for 4 hours.
Ordering
Cerner Orderable(s)
P2Y12 Platelet Function
Performed
Morton Plant Hospital and St. Joseph's Hospital
24/7
Ordering Recommendations
The P2Y12 Assay is designed to measure platelet P2Y12 receptor blockade. Substances known to specifically block the P2Y12 receptor include the thienopyridine class of drugs, including clopidogrel (Plavix®)
Methodology
The assay is based on the ability of activated platelets to bind fibrinogen. Fibrinogen-coated microparticles aggregate in whole blood in proportion to the number of expressed platelet GPIIb/IIIa receptors. The reagent is formulated to specifically measure P2Y12-mediated platelet aggregation. Light transmittance increases as activated platelets bind and aggregate fibrinogen-coated beads. The instrument measures this change in optical signal and reports results in P2Y12 Reaction Units (PRU).
Result Interpretation
Reference Interval
P2Y12 Plt Function Reference Interval: 194-418 PRU
Interpretive Data
Test results are reported in P2Y12 Reaction Units (PRU). The PRU is a measure of platelet aggregation in the presence of P2Y12 inhibitor drug. A lower PRU is associated with a higher platelet blockade by the inhibitor. Data in the literature suggests that a PRU of greater than 208 may be associated with a higher risk of adverse events in a patient that has received percutaneous coronary intervention. However, as there is inter-individual variability in this assay, the test should be interpreted in the clinical context.
Glycoprotein IIb/IIIa inhibitor drugs can interfere with this assay. The test should not be used in patients until 14 days after discontinuation of abciximab and until 48 hours after discontinuation of eptifibatide and triofiban.
This assay is not intended for evaluation of inherited platelet disorders, such as Von Willebrand Factor Deficiency, Glanzmann Thrombasthenia and Bernard-Soulier Syndrome.
